



SCIENTIFIC LETTERS

Autosomal recessive polycystic kidney disease in the 21st century: Long-term follow-up and outcomes[☆]



Poliquistosis renal autosómica recesiva en el siglo XXI: seguimiento y evolución a largo plazo

Dear Editor:

Autosomal recessive polycystic kidney disease (ARPKD) is very important in paediatrics on account of its severity and the early morbidity and mortality it produces. There is considerable variability in its phenotypic expression, most patients are de novo cases, and the exact relationship between genotype and phenotype has yet to be established.¹ Due to all of the above, this disease causes a high level of anxiety in families concerning the child's prognosis, as well as a high demand for genetic counselling.

The aim of our study was to provide a retrospective description of a cohort of paediatric patients with ARPKD managed in a single hospital over a 25-year period. We also sought to identify associations between different clinical manifestations and long-term outcomes.

We made a retrospective search to identify patients with a diagnosis of ARPKD followed up in the department of paediatric nephrology between January 1991 and December 2016. The sample included 16 patients (12 male and 4 female) with a median age of 16.5 years at the time of the study. In this sample, 62% of cases were diagnosed before birth based on sonographic findings. The most frequent sonographic feature found in our sample was renal enlargement (75% of cases), followed by the presence of visible renal cysts (72%).

Two patients underwent genetic testing, which identified a R1804fs mutation in gene *PKHD1* in one and a double heterozygous mutation in the *PKHD1* gene in the other (NM_138694.3: c.3350_3351delTA NP_619639: p.I1117Kfs*7/NM_138694.3: c.3765_3766delinsG NP_619639: p.Q1256Rfs*47).

Two patients died in the neonatal period due to respiratory failure secondary to pulmonary hypoplasia. The 14 remaining patients survive to date. Of these patients, 57% have developed chronic kidney disease (CKD). The median

age of this subgroup at the time of this writing is 22.9 years (Table 1).

We ought to highlight the rapid progression of disease in the patient with a molecular diagnosis of a double heterozygous mutation, which was consistent with previous studies² that have described more severe phenotypes in association with the presence of 2 truncating mutations in the *PKHD1* gene.

On the other hand, 43% of the sample has yet to develop CKD, and the median age of this subgroup is 12.3 years (Table 2).

We did not find an association between renal size and liver involvement or high blood pressure (HBP) and/or proteinuria. We also found no association between prenatal diagnosis and the development of CKD.

We did find an association between kidney enlargement at the time of diagnosis and future development of CKD (OR, 3.5; 95% CI, 0.24–51.9), although it was not statistically significant (Fisher exact test, $P = .53$).

In our study, mortality in patients with ARPKD was associated with neonatal pulmonary hypoplasia. Survival was high after the neonatal period. This is consistent with previous reports in the literature,³ although previous authors reported a higher mortality compared to the one found in our sample. This improvement in survival may be due to previous studies⁴ being a few years older and not reflecting the impact of recent advances in neonatal care and of the follow-up of patients in specialised referral units. Prenatal diagnosis, which occurs in most cases at present, and the option of terminating the pregnancy constitute another factor that needs to be taken into account when it comes to the epidemiology of ARPKD.

The morbidity found in survivors of ARPKD is due to HBP that is difficult to control and the development of CKD and liver disease, whereas lung function develops correctly. In agreement with the literature, more than 50% of the patients progressed to CKD. In previously published case series,⁵ kidney impairment developed in the first decade of life, but in our sample 43% of the patients had normal renal function past age 10 years.

Several authors⁶ have suggested that renal size could be a parameter indicative of severity of disease. In our sample, we found an association between kidney enlargement and the development of CKD, although it was not statistically significant, a fact that could be due to the small sample size.

Our study shows that ARPKD is a chronic disease that is treatable and with long-term patient survival past the neonatal period, manifesting with clinically significant HBP of early onset and, in rare cases, with severe proteinuria.

[☆] Please cite this article as: Rubio San Simón A, Carbayo Jiménez T, Vara Martín J, Alonso Díaz C, Espino Hernández M. Poliquistosis renal autosómica recesiva en el siglo XXI: seguimiento y evolución a largo plazo. An Pediatr (Barc). 2019;91:120–122.

Table 1 Summary of the data collected for the main variables under study in the group of patients with CKD.

Patient	Current age	Sex	Prenatal DX	Genetic testing	Age at onset of CKD	Stage of CKD	Liver involvement	Renal size	HBP	Proteinuria	Transplant
1	23	M	Yes	—	19	2	Liver fibrosis	↑	Yes	No	
2	1	F	Yes	Double heterozygous mutation in <i>PKHD1</i>	1	3	Liver fibrosis + PH	↑	Yes (2 AHT drugs)	Yes	
3	4	F	No	—	3	2	Liver fibrosis	↑	No	No	
4	26	M	Yes	—	12	5	Liver fibrosis + PH	↑	Yes (>2 AHT drugs)	Yes	Liver–kidney at age 22 years
5	5	M	Yes	R1804fs in <i>PKHD1</i>	2	2	Liver fibrosis	↑	Yes (>2 AHT drugs)	No	
6	26	M	No	—	11	3	BA	Normal	Yes	Yes	Liver at age 3 years
7	29	M	No	—	8	5	Liver fibrosis + PH + choledochal cysts	↑	Yes (>2 AHT drugs)	Yes	Liver–kidney at age 15 years
8	22	F	Yes	—	5	5	Liver fibrosis + PH + choledochal cysts	↑	No	Yes	Kidney at age 15 years

HBP, high blood pressure; AHT drugs, antihypertensive drugs; BA, biliary atresia; CKD, chronic kidney disease; DX, diagnosis; F, female; M, male; PH, portal hypertension. Current age: age in years at the time of the study; age at onset of CKD: age in years at the time of onset of CKD.

Table 2 Summary of the data collected for the main variables under study in the group of patients without CKD.

Patient	Current age	Sex	Prenatal DX	Genetic testing	Liver involvement	Renal size	HBP	Proteinuria	Transplant
1	0.8	M	Yes	—	No	↑	No	Yes	—
2	9	F	No	—	Liver fibrosis + PH	↑	Yes (2 AHT drugs)	Yes	—
3	4	M	Yes	—	No	Normal	No	No	—
4	23	M	No	—	Liver fibrosis	↑	Yes (1 AHT drugs)	Yes	—
5	18	M	Yes	—	No	Normal	Yes (1 AHT drugs)	No	—
6	16	M	No	—	No	↑	No	Yes	—

HBP, high blood pressure; AHT drugs, antihypertensive drugs; CKD, chronic kidney disease; DX, diagnosis; F, female; M, male; PH, portal hypertension.

Current age: age in years at the time of the study.

Chief among the limitations of our study is the small sample size, which precludes the extrapolation of our findings to the larger population and reduced the statistical power of the analyses. In addition, only 2 patients underwent genetic testing, which limited our ability to draw conclusions regarding the role of genetic testing in the management of this disease.

References

- Melchionda S, Palladino T, Castellana S, Giordano M, Benetti E, de Bonis P, et al. Expanding the mutation spectrum in 130 probands with ARPKD: identification of 62 novel PKHD1 mutations by sanger sequencing and MLPA analysis. *J Hum Genet.* 2016;61: 811–21.
- Guay-Woodford LM. Autosomal recessive polycystic kidney disease: the prototype of the hepato-renal fibrocystic diseases. *J Pediatr Genet.* 2014;3:89–101.
- Guay-Woodford L. Other cystic diseases. In: Johnson R, Feehally J, editors. *Comprehensive clinical nephrology.* 4th ed. London: Mosby; 2010. p. 543–59.
- Guay-Woodford LM, Desmond RA. Autosomal recessive polycystic kidney disease: the clinical experience in North America. *Pediatrics.* 2003;111:1072–80.
- Hoyer PF. Clinical manifestations of autosomal recessive polycystic kidney disease. *Curr Opin Pediatr.* 2015;27:186–92.
- Liebau MC, Serra AL. Looking at the (w)hole: magnet resonance imaging in polycystic kidney disease. *Pediatr Nephrol.* 2013;28:1771–3.

Alba Rubio San Simón*, Tania Carbayo Jiménez, Julia Vara Martín, Clara Alonso Díaz, Mar Espino Hernández

Hospital Universitario 12 de Octubre, Madrid, Spain

* Corresponding author.

E-mail address: arubiosansimon@gmail.com

(A. Rubio San Simón).

2341-2879/

© 2019 Published by Elsevier España, S.L.U. on behalf of Asociación Española de Pediatría. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

How do we treat Kaposiform haemangioendothelioma?☆



¿Cómo tratamos el hemangioendoteloma kaposiforme?

Dear Editor:

Kaposiform haemangioendothelioma (KHE) is a rare, vascular tumour that has little metastatic potential but can be locally aggressive and may be life-threatening. It is diagnosed based on the findings of imaging tests and gross and histological features. It usually presents as a single lesion in the retroperitoneum or subcutaneous tissue, and in 30% of cases it is associated with Kasabach–Merritt syn-

drome (KMS), a coagulopathy that has complications that are more severe than those of KHE alone. The Sociedad Española de Hematología y Oncología Pediátrica (Spanish Society of Paediatric Haematology and Oncology) proposes surgical resection as first-line treatment, but the involvement of vital structures may preclude this option. In such cases, the use of a combination of antiplatelet therapy and systemic corticosteroid therapy is recommended for first-line treatment, reserving treatment with vincristine, cyclophosphamide, interferon alfa or other cytostatic agents for refractory cases.¹

We present the 3 cases of KHE managed in the past decade in our tertiary care hospital, one of whom was a patient with underlying sickle cell disease, a comorbidity that has not been described previously.

Case 1: full-term infant with a congenital violaceous cervical mass, hard to de touch and extending from the left retroauricular area to the edge of the right preauricular area (Fig. 1). A magnetic resonance image (MRI) scan confirmed the diagnosis of KHE (Fig. 2). The patient presented with thrombocytopenia (25 000/dL) and D-dimer elevation (3000 µg/L), which suggested the additional

☆ Please cite this article as: Huerta-Calpe S, Pinilla-González A, Juan Ribelles A, Gómez-Chacón Villalba J, Pérez-Tarazona S. ¿Cómo tratamos el hemangioendoteloma kaposiforme? *An Pediatr (Barc).* 2019;91:122–124.